Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole versus teprenone after allogeneic haploidentical HSCT for prevention of acute graft-versus-host disease
ChiCTR2600132304Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esomeprazole and teprenone in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of acute graft-versus-host disease post-transplantation. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
esomeprazoleteprenone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2600132304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132304.